---
layout: default
title: Copper Chloride
parent: 僅模型預測 (L5)
nav_order: 146
evidence_level: L5
indication_count: 0
---

# Copper Chloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Copper Chloride: Drug Repurposing Evaluation — Insufficient Data for Assessment

---

## One-Sentence Summary

Copper Chloride is an inorganic copper salt with potential roles as a trace element supplement and experimental agent; however, its established therapeutic indications are not documented in this Evidence Pack.
The TxGNN model did **not generate any predicted new indications** for this compound at this time, likely due to the absence of a DrugBank ID and missing regulatory linkage data.
As a result, **no supporting clinical trials or publications** can be presented, and a full repurposing evaluation cannot be completed without first resolving the identified data gaps.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not established in this dataset |
| Predicted New Indication | None — TxGNN returned no candidates |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction unavailable; no supporting studies) |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Clinical Trial Evidence

Currently no related clinical trials registered for Copper Chloride under any predicted indication.

---

## Literature Evidence

Currently no related literature available linked to a TxGNN-predicted repurposing indication.

---

## South Africa Market Information

Copper Chloride is **not currently registered with SAHPRA** and has no active product licences in South Africa. There are no approved Professional Information (PI) documents available through the local regulatory pathway.

---

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information once registration is pursued. Report adverse drug reactions to SAHPRA via the MedSafety reporting system.

> **Note:** Known general considerations for copper salts include risk of acute copper toxicity at high doses (hepatotoxicity, haemolysis), interaction with zinc supplementation (competitive absorption), and caution in patients with Wilson's disease or hepatic impairment. These are provided for contextual awareness only and do not substitute for a full pharmacovigilance assessment.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline returned zero predicted indications for Copper Chloride, most likely because the compound lacks a DrugBank ID — a prerequisite for knowledge graph traversal and disease-node scoring. Without a valid prediction, no evidence-based repurposing pathway can be evaluated or recommended at this stage.

**To proceed, the following is needed:**

- **Resolve DrugBank ID** — Confirm whether Copper Chloride maps to an existing DrugBank entry (e.g., DB09130 for copper, or a specific salt form) and rerun the TxGNN mapping pipeline with the correct identifier.
- **Confirm original indication(s)** — Determine the authorised or investigational therapeutic context for this compound (e.g., trace element supplementation in parenteral nutrition, wound care, or diagnostic use).
- **Obtain mechanism of action (MOA) data** — Query the DrugBank API for pharmacological category, targets, and MOA to enable mechanistic plausibility analysis.
- **Retrieve SAHPRA/PI safety data** — Source and parse the relevant Professional Information or international SmPC to populate key warnings, contraindications, and drug interaction profiles.
- **Re-submit Evidence Pack** — Once the above data gaps (DG001: safety warnings; DG002: MOA) are resolved, rerun the full TxGNN pipeline to generate repurposing candidates and a complete evidence-graded report.

---

*This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before therapeutic application. Data cutoff: 2026-04-05.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

